Clinical Trial

Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

Study acronym: MYTHIC
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with Debio 0123 in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2021-04-19; most recent amendment 2026-07-23.
Status change: Not Yet Recruiting → Recruiting 2021-05-12
Trial Details
NCT Number NCT04855656
Lead Sponsor Debiopharm International SA
Conditions Advanced Solid Tumor
Enrollment 464 participants
Start Date 2021-04-30
Primary Completion 2027-12 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-24